WeVote

Bill

Bill

HB 800

Active Pharmaceutical Ingredient Manufacturing Grant Fund; established.

2026 Regular Session Introduced by Virgil Thornton and 1 co-sponsor

Virginia creates a state grant fund to subsidize active pharmaceutical ingredient manufacturing facilities, aiming to strengthen domestic drug supply chains and generate manufacturing jobs.

Approved by Governor-Chapter 804 (effective 7/1/2026)
0
WeVote Research Nonpartisan
Bill Summary · HB 800

Legislative bill overview

HB 800 establishes a grant fund in Virginia to support the manufacturing of active pharmaceutical ingredients (APIs)—the core chemical compounds used to produce medications. The bill provides state financial incentives to encourage pharmaceutical manufacturers to develop or expand API production facilities within Virginia.

Why is this important

Domestic API manufacturing has become a critical policy priority following supply chain disruptions exposed during the COVID-19 pandemic. Currently, the U.S. imports approximately 80% of its APIs, creating vulnerabilities to geopolitical tensions and trade disputes. Virginia's initiative aims to increase drug security, create high-wage manufacturing jobs, and potentially position the state as a regional pharmaceutical hub.

Potential points of contention

  • Cost-benefit uncertainty: The bill's actual economic impact depends on grant award amounts and whether it successfully attracts major manufacturers versus subsidizing marginal expansions that would occur anyway
  • Long-term fiscal commitment: Establishing a grant fund creates ongoing budget obligations; unclear if the fund has caps, sunset provisions, or performance metrics to measure return on state investment
  • Market viability questions: API manufacturing is capital-intensive and typically profit-driven; debate exists over whether government grants are necessary or if companies would invest regardless in strategic locations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.